Blue Trust Inc’s Emergent Biosolutions EBS Stock Holding History

Blue Trust Inc’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-94	Closed	–	–	2331
2023 Q4	$0	Buy	+94	New	+$221	﹤0.01%	2540
2023 Q2	–	Sell	-41	Closed	–	–	2140
2023 Q1	$0	Buy	+41	New	+$496	﹤0.01%	2392

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Blue Trust Inc's EBS Position: Q1 2024 in Review

Blue Trust Inc sold out of Emergent Biosolutions (EBS) in Q1 2024, closing a stake of 94 shares.

Blue Trust Inc first reported a position in EBS in Q1 2023 and held it in 2 quarters. The position peaked at $0 in Q4 2023. 122 funds tracked by Wall St. Rank hold EBS as of Q1 2024.

Blue Trust Inc reported no remaining Emergent Biosolutions position as of Q1 2024 after selling out during the quarter.
Blue Trust Inc sold 94 Emergent Biosolutions shares in Q1 2024.
Blue Trust Inc first reported a position in Emergent Biosolutions in Q1 2023 and held it in 2 quarters.
Blue Trust Inc's Emergent Biosolutions position peaked at $0 in Q4 2023.
122 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2024.

Based on Blue Trust Inc's 13F filing for Q1 2024, filed 1 May 2024.